AR091739A1 - COMPOSITIONS AND METHODS TO REDUCE CARDIOMETABOLIC RISK - Google Patents

COMPOSITIONS AND METHODS TO REDUCE CARDIOMETABOLIC RISK

Info

Publication number
AR091739A1
AR091739A1 ARP130102472A AR091739A1 AR 091739 A1 AR091739 A1 AR 091739A1 AR P130102472 A ARP130102472 A AR P130102472A AR 091739 A1 AR091739 A1 AR 091739A1
Authority
AR
Argentina
Prior art keywords
compositions
methods
cardiometabolic risk
reduce
reduce cardiometabolic
Prior art date
Application number
Other languages
Spanish (es)
Inventor
S Fineman Mark
D Baron Alain
R A Beeley Nigel
Original Assignee
Elcelyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/547,022 external-priority patent/US8796338B2/en
Priority claimed from US13/734,966 external-priority patent/US9211263B2/en
Application filed by Elcelyx Therapeutics Inc filed Critical Elcelyx Therapeutics Inc
Publication of AR091739A1 publication Critical patent/AR091739A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones y métodos que comprenden por lo menos un compuesto biguanida y por lo menos una estatina en combinación con por lo menos un agente activo adicional en combinaciones de dosis fijas para reducir el riesgo cardiometabólico, y para el tratamiento de la enfermedad cardiovascular, en donde el compuesto biguanida está formulado para una liberación retardada.Compositions and methods comprising at least one biguanide compound and at least one statin in combination with at least one additional active agent in fixed dose combinations to reduce cardiometabolic risk, and for the treatment of cardiovascular disease, wherein the Biguanide compound is formulated for delayed release.

ARP130102472 2012-07-11 2013-07-11 COMPOSITIONS AND METHODS TO REDUCE CARDIOMETABOLIC RISK AR091739A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/547,022 US8796338B2 (en) 2011-01-07 2012-07-11 Biguanide compositions and methods of treating metabolic disorders
US13/734,966 US9211263B2 (en) 2012-01-06 2013-01-05 Compositions and methods of treating metabolic disorders

Publications (1)

Publication Number Publication Date
AR091739A1 true AR091739A1 (en) 2015-02-25

Family

ID=48833086

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102472 AR091739A1 (en) 2012-07-11 2013-07-11 COMPOSITIONS AND METHODS TO REDUCE CARDIOMETABOLIC RISK

Country Status (9)

Country Link
EP (1) EP2872127A1 (en)
JP (2) JP2015522080A (en)
CN (1) CN104780915A (en)
AR (1) AR091739A1 (en)
AU (1) AU2013290100A1 (en)
CA (1) CA2878625A1 (en)
HK (1) HK1210825A1 (en)
IL (1) IL236647A0 (en)
WO (1) WO2014011926A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2751834C (en) 2009-02-13 2018-07-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
AR085689A1 (en) 2011-03-07 2013-10-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (en) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Therapeutic uses of empagliflozin
KR102309654B1 (en) 2013-04-18 2021-10-08 베링거 인겔하임 인터내셔날 게엠베하 Pharmaceutical composition, methods for treating and uses thereof
CN111818911B (en) * 2017-12-26 2022-11-18 广东东阳光药业有限公司 Lurasidone solid dispersion and preparation method thereof

Family Cites Families (275)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS58403B2 (en) 1975-07-24 1983-01-06 武田薬品工業株式会社 L- Ascorbine Sanseizaino Seizouhou
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5135757A (en) 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
FR2704146B1 (en) 1993-04-19 1995-07-13 Cripdom Microcapsules of acetylsalicylic acid with controlled release.
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
FR2725623A1 (en) 1994-10-18 1996-04-19 Flamel Tech Sa MEDICINAL AND / OR NUTRITION MICROCAPSULES FOR PER OS ADMINISTRATION
ATE344046T1 (en) 1997-04-15 2006-11-15 Csir PLANT EXTRACTS WITH APPETITE SUPPRESSING ACTIVITY
US5891919A (en) 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US6180365B1 (en) 1998-11-06 2001-01-30 Smithkline Beecham Corporation Polynucleotide encoding a Mouse 7-transmembrane GPR43 receptor
ITMI991316A1 (en) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF MESALAZINE
IL132313A0 (en) 1999-10-11 2001-03-19 Yeda Res & Dev Leptin assay
AU2001232132A1 (en) 2000-02-18 2001-08-27 Glaxo Group Limited Novel assay
US20110217394A1 (en) 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
US7998947B2 (en) 2001-03-28 2011-08-16 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
US8030008B2 (en) 2001-04-05 2011-10-04 Senomyx, Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
EP1463759B8 (en) 2002-01-07 2013-07-10 Euroscreen S.A. Ligand for g-protein coupled receptor gpr43 and uses thereof
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
US20060019346A1 (en) 2002-07-29 2006-01-26 Senomyx, Inc. Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands
EP1549296A4 (en) * 2002-08-02 2006-08-09 Penwest Pharmaceuticals Co Sustained release formulations of metformin
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
ATE429915T1 (en) 2002-10-10 2009-05-15 Arena Pharm Inc 5-SUBSTITUTED 2H-PYRAZONE-3-CARBONIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC DISORDERS, SUCH AS DYSLIPIDEMIA
WO2004038405A2 (en) 2002-10-25 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
WO2004038421A2 (en) 2002-10-25 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
EP1559422B1 (en) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
CN1413582A (en) * 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 Dimethyldiguanide hydrochloride enteric solubility tablet and its preparation method
DE60320682T2 (en) 2002-12-18 2009-06-10 Givaudan S.A. CHIMERIC ALPHA Q-GUSTDUCINE G PROTEINS
WO2004072650A1 (en) 2003-02-17 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 40 (gpr40)
DE10308504A1 (en) 2003-02-26 2004-09-09 Basf Ag Enzymatic production of (meth) acrylic acid esters
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
AU2004260636A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor RUP25 for the treatment of dyslipidemia and related diseases
WO2005009351A2 (en) 2003-07-17 2005-02-03 Santé International, Inc. Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabetics
AU2003269484A1 (en) * 2003-09-11 2005-03-29 Biocon Limited Salt of atorvastatin with metformin
WO2005028488A1 (en) 2003-09-12 2005-03-31 Quatrx Pharmaceuticals Co. Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
AU2004293415A1 (en) 2003-11-21 2005-06-09 Arena Pharmaceuticals, Inc. 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (en) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
JP4859665B2 (en) 2004-03-30 2012-01-25 武田薬品工業株式会社 Alkoxyphenylpropanoic acid derivatives
KR20070053659A (en) 2004-04-20 2007-05-25 도이체스 인스티튜트 퓌어 에른에룬그스포슝 Agonists of a bitter taste receptor and uses thereof
JP2007284350A (en) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd Therapeutic agent for diabetes
US20060024335A1 (en) 2004-07-29 2006-02-02 Roger Stier E Oral compositions which mask the bitter taste of a bitter-tasting agent
SG155896A1 (en) 2004-09-22 2009-10-29 Arena Pharm Inc Gpr43 and modulators thereof for the treatment of metabolic-related disorders
WO2006038738A1 (en) 2004-10-08 2006-04-13 Takeda Pharmaceutical Company Limited Receptor function regulating agent
ES2498972T3 (en) 2004-11-03 2014-09-26 Arena Pharmaceuticals, Inc. GPR41 and its modulators for the treatment of insulin-related disorders
WO2006053771A2 (en) 2004-11-18 2006-05-26 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Stiftung Des Öffentlichen Rechts Agonists of bitter taste receptors and uses thereof
PE20060949A1 (en) 2004-12-23 2006-10-11 Arena Pharm Inc FUSED DERIVATIVES OF PIRAZOLE AS NIACIN RECEPTOR AGONISTS
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
CA2593788A1 (en) 2005-01-28 2006-08-10 Merck And Co., Inc. Antidiabetic bicyclic compounds
JP2008528628A (en) 2005-01-31 2008-07-31 メルク エンド カムパニー インコーポレーテッド Antidiabetic bicyclic compound
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
WO2006102653A2 (en) 2005-03-24 2006-09-28 Irm Llc Methods and compositions for treating insulin resistance and obesity-induced diseases
AU2006241684A1 (en) 2005-04-28 2006-11-09 Ajinomoto Co., Inc. Novel lactam compound
EP1899304A1 (en) 2005-05-23 2008-03-19 Arena Pharmaceuticals, Inc. 5-amino-1h-pyrazole-3-carboxylic acid derivatives as agonists for the g-protein coupled receptor (gpcr) rup38 for the treatment of metabolic-related disorders thereof
US20060269617A1 (en) 2005-05-26 2006-11-30 Suracell, Inc. Supplement compositions and method of use for enhancement of insulin sensitivity
US7939276B2 (en) 2005-06-22 2011-05-10 Senomyx, Inc. Assays which screen for compounds that modulate bitter taste of chlorogenic lactone compounds
WO2007014824A1 (en) 2005-07-28 2007-02-08 Nestec S.A. Fat taste receptors and their methods of use
JP5084503B2 (en) 2005-07-29 2012-11-28 武田薬品工業株式会社 Cyclopropanecarboxylic acid compound
EP1924709A1 (en) 2005-08-10 2008-05-28 Arena Pharmaceuticals, Inc. Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist
US8399204B2 (en) 2005-09-02 2013-03-19 Eisai R&D Management Co., Ltd. Method for screening of substance which alter GPR120-mediated cell-stimulating activities
WO2007049050A2 (en) 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
US20070104805A1 (en) 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
JP2007215162A (en) 2006-01-11 2007-08-23 Canon Inc Information processing apparatus, control method thereof, program and recording medium
US20070207227A1 (en) 2006-02-23 2007-09-06 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Appetite suppressant compositions
AU2007235673A1 (en) 2006-04-06 2007-10-18 Prosidion Limited Heterocyclic GPCR agonists
WO2007116404A2 (en) 2006-04-10 2007-10-18 Bar-Ilan University Cucurbitacin glucosides and use thereof in treating cancer
KR101281962B1 (en) 2006-04-11 2013-07-08 아레나 파마슈티칼스, 인크. Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
CA2651153C (en) 2006-05-15 2014-04-29 Merck & Co., Inc. Antidiabetic bicyclic compounds
WO2007134613A1 (en) 2006-05-24 2007-11-29 Rheoscience A/S Modulation of gpr120 activity in adipocytes/fat tissue
UA95296C2 (en) 2006-06-27 2011-07-25 Такеда Фармасьютікал Компані Лімітед Fused cyclic compounds
CA2551706A1 (en) 2006-06-27 2007-12-27 Innovative Life Sciences Corporation Herbal product comprising cinnamon and bitter melon
CN100596277C (en) 2006-07-10 2010-03-31 博仲盛景医药技术（北京）有限公司 Medicinal composition for promoting enterogastric peristalsis
CN101511429A (en) 2006-07-13 2009-08-19 史密丝克莱恩比彻姆公司 Indulines derivatives and gpr119 agonists
AP2518A (en) 2006-08-17 2012-11-28 Unilever Plc Processes for production of hoodia plant extracts containing steroidal glycosides
WO2008022875A1 (en) 2006-08-24 2008-02-28 Unilever N.V. Process for preparing a composition comprising steroidal glycosides
AU2007291252A1 (en) 2006-08-30 2008-03-06 Inovacia Ab Pyridine compounds for treating GPR119 related disorders
CN101522702A (en) 2006-09-05 2009-09-02 塞诺米克斯公司 Novel haplotype of human t2r receptor ht2r50 and its use in assays for identifying human bitter taste modulators
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
WO2008063321A2 (en) 2006-10-13 2008-05-29 Janssen Pharmaceutica N.V. Gpr81-ligand complexes and their preparation and use
AU2007314405A1 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
WO2008054674A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
BRMU8602999U (en) * 2006-11-16 2008-07-08 Walter Junior Santos medicine "rosuvastatin + metformin" in combination form for cardiovascular disease
WO2008058355A2 (en) * 2006-11-16 2008-05-22 Walter Santos Junior Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases
CN101190179B (en) * 2006-11-20 2010-05-12 北京利龄恒泰药业有限公司 Enteric medicinal composition for treating diabetes and preparation method thereof
TW200838526A (en) 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
AU2007326395B2 (en) 2006-12-01 2012-10-11 Msd K.K. Novel phenyl-isoxazol-3-ol derivative
CN105152983A (en) * 2007-01-29 2015-12-16 韩诺生物制药株式会社 N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
EP2121675A1 (en) 2007-02-22 2009-11-25 Irm Llc Thiazole derivatives as modulators of g protein-coupled receptors
DE602008002733D1 (en) 2007-03-08 2010-11-04 Irm Llc COMPOUNDS AND COMPOSITIONS AS MODULATORS OF THE GPR119 ACTIVITY
EP1975612A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
EP1975611A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
JP2010524932A (en) 2007-04-16 2010-07-22 アムジエン・インコーポレーテツド Substituted biphenylphenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators
JP2010524944A (en) 2007-04-20 2010-07-22 シェーリング コーポレイション Tetrahydropyrido [4,3-d] pyrimidinone derivatives and methods for their use
US20100190687A1 (en) 2007-04-20 2010-07-29 Boyle Craig D Pyrimidinone derivatives and methods of use thereof
JP2010524941A (en) 2007-04-20 2010-07-22 シェーリング コーポレイション Pyrimidinone derivatives and methods for their use
US8318781B2 (en) 2007-04-26 2012-11-27 Japan Science And Technology Agency G-protein-conjugated receptor agonist
US7910583B2 (en) 2007-05-04 2011-03-22 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
WO2008137436A1 (en) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
US8309534B2 (en) 2007-05-15 2012-11-13 Medical College Of Georgia Research Institute, Inc. Compositions comprising a GPR109 ligand for treating disorders of the digestive tract and/or cancer
SI2170864T1 (en) 2007-07-17 2012-04-30 Bristol Myers Squibb Co Pyridone gpr119 g protein-coupled receptor agonists
JP5489997B2 (en) 2007-07-19 2014-05-14 シマベイ セラピューティクス， インコーポレーテッド N-aza cyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of RUP3 or GPRl 19 receptors for the treatment of diabetes and metabolic diseases
US20090042813A1 (en) 2007-08-10 2009-02-12 Sergey Michailovich Melnikov Hoodia extract oil compositions comprising medium chain triglycerides
WO2009033078A2 (en) 2007-09-05 2009-03-12 Raif Tawakol Compositions and methods for controlling cholesterol levels
JP2010539152A (en) 2007-09-10 2010-12-16 プロシディオン・リミテッド Compounds for the treatment of metabolic disorders
WO2009038204A1 (en) 2007-09-17 2009-03-26 Pharma Frontier Co., Ltd. Novel long-chain fatty acid derivative compound and g-protein-coupled receptor agonist containing the compound as active ingredient
WO2009038974A1 (en) 2007-09-20 2009-03-26 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009048527A1 (en) 2007-10-10 2009-04-16 Amgen Inc. Substituted biphenyl gpr40 modulators
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
EP2217596B8 (en) 2007-10-22 2013-11-20 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
JP2011016722A (en) 2007-10-23 2011-01-27 Astellas Pharma Inc Thiazolidinedione compound
US20100316736A1 (en) 2007-10-24 2010-12-16 Desert Labs Agriculture Cooperative Association Ltd. Appetite suppressant
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
US8399507B2 (en) 2007-10-29 2013-03-19 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP5075211B2 (en) 2008-01-29 2012-11-21 中森製薬株式会社 Pharmaceutical composition
EP2252586A1 (en) 2008-02-22 2010-11-24 Irm Llc Compounds and compositions as modulators of gpr119 activity
CN102007126A (en) 2008-02-22 2011-04-06 Irm责任有限公司 Compounds and compositions as modulators of gpr119 activity
CN102006870A (en) 2008-02-22 2011-04-06 Irm责任有限公司 Compounds and compositions as modulators of gpr119 activity
WO2009106561A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
WO2009106565A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Agonists of gpr119
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CA2719507C (en) 2008-03-31 2018-03-27 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
KR20100137561A (en) 2008-04-07 2010-12-30 아이알엠 엘엘씨 Compounds and compositions as modulators of gpr119 activity
WO2009125804A1 (en) 2008-04-09 2009-10-15 武田薬品工業株式会社 Screening method
WO2009143049A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
WO2009140784A1 (en) 2008-05-23 2009-11-26 Givaudan Sa Bitter alkaloid containing consumables comprising bitter blockers
US20110071198A1 (en) 2008-05-27 2011-03-24 Lefkowitz Robert J Nicotinic acid receptor ligands
CN101695575A (en) * 2008-05-29 2010-04-21 北京奥萨医药研究中心有限公司 Pharmaceutical composition containing statin-type lipid-lowering medicaments, phenformin-type hypoglycemic medicaments and nicotinic acid
AU2009255183A1 (en) 2008-06-02 2009-12-10 Msd K.K. Novel isoxazole derivative
WO2009150144A1 (en) 2008-06-10 2009-12-17 Inovacia Ab New gpr119modulators
EP2300830B1 (en) 2008-06-13 2015-05-20 Givaudan SA Methods of identifying modulators of the bitter taste receptor tas2r44
EP2303859A4 (en) 2008-06-20 2012-08-22 Metabolex Inc Aryl gpr119 agonists and uses thereof
GB0812031D0 (en) 2008-07-01 2008-08-06 7Tm Pharma As Thiazole derivatives
GB0812649D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
EP2331503B1 (en) 2008-07-11 2013-08-21 Irm Llc 4-phenoxymethylpiperidines as modulators of gpr119 activity
US8822480B2 (en) 2008-07-16 2014-09-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2010012650A1 (en) 2008-07-28 2010-02-04 Syddansk Universitet Compounds for the treatment of metabolic diseases
WO2010013849A1 (en) 2008-08-01 2010-02-04 日本ケミファ株式会社 Gpr119 agonist
US8557530B2 (en) 2008-08-29 2013-10-15 Givaudan Sa Use of a TAS2R7 nucleic acid sequence to identify modulators
US8901166B2 (en) 2008-08-29 2014-12-02 Suntory Holdings Limited Epigallocatechin gallate tetramer and vascular endothelial function improving agent containing the same
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
US8748462B2 (en) 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
BRPI0920237A2 (en) 2008-10-21 2015-12-29 Metabolex Inc aril gpr120 receptor agonists and their respective uses
WO2010060198A1 (en) 2008-11-26 2010-06-03 West Central Envirotech Inc. Composition and method for controlling insects
AR074760A1 (en) 2008-12-18 2011-02-09 Metabolex Inc GPR120 RECEIVER AGONISTS AND USES OF THE SAME IN MEDICINES FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME.
WO2010074271A1 (en) 2008-12-26 2010-07-01 武田薬品工業株式会社 Therapeutic agent for diabetes
EP2385049A4 (en) 2009-01-03 2012-08-08 Shizuoka Prefecture Public University Corp Sulfated c-glycoside, method for isolating same and method for synthesizing same
JPWO2010084944A1 (en) 2009-01-22 2012-07-19 田辺三菱製薬株式会社 Novel pyrrolo [2,3-d] pyrimidine compounds
US20110312995A1 (en) 2009-01-23 2011-12-22 Schering Corporation Bridged and fused heterocyclic antidiabetic compounds
US20110312967A1 (en) 2009-01-23 2011-12-22 Schering Corporation Bridged and fused antidiabetic compounds
US20110313008A1 (en) 2009-01-23 2011-12-22 Schering Corporation Pentafluorosulpholane-containing antidiabetic compounds
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US8575166B2 (en) 2009-02-05 2013-11-05 Merck Sharp & Dohme Corp. Phthalazine-containing antidiabetic compounds
EP2399914A4 (en) 2009-02-18 2012-08-29 Takeda Pharmaceutical Fused heterocyclic ring compound
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
JP2012520868A (en) 2009-03-20 2012-09-10 ファイザー・インク 3-Oxa-7-azabicyclo [3.3.1] nonane
JP2012136438A (en) 2009-04-22 2012-07-19 Astellas Pharma Inc Tetrazole compound
JPWO2010123016A1 (en) 2009-04-22 2012-10-25 アステラス製薬株式会社 Carboxylic acid compound
JP2012136439A (en) 2009-04-24 2012-07-19 Nippon Chemiphar Co Ltd Diazaspiroalkane derivative
US20120052130A1 (en) 2009-05-08 2012-03-01 Pfizer Inc. Gpr 119 modulators
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
BRPI1014636A2 (en) 2009-06-05 2016-04-05 Pfizer gpr modulators 119
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
AR077638A1 (en) 2009-07-15 2011-09-14 Lilly Co Eli COMPOSITE OF (METHANOSULPHONYL -PIPERIDIN) - (ALCOXI-ARIL) -TETRAHIDRO- PYRIDINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF DIABETES OR OBESITY
US8709745B2 (en) 2009-07-28 2014-04-29 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Methods for isolating ligands of the human bitter taste receptor TAS2R49
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
US20120245344A1 (en) 2009-08-31 2012-09-27 Nippon Chemiphar Co., Ltd. Gpr119 agonist
KR101685734B1 (en) 2009-09-01 2016-12-12 카타베이시스 파마슈티칼즈, 인코포레이티드 Fatty acid niacin conjugates and their uses
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
JP2013505290A (en) 2009-09-23 2013-02-14 ファイザー・インク GPR119 regulator
WO2011044139A1 (en) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Fatty acid acifran derivatives and their uses
US20110082156A1 (en) 2009-10-05 2011-04-07 Milne Jill C Fatty acid acipimox derivatives and their uses
MX2012003389A (en) 2009-10-06 2012-04-10 Bristol Myers Squibb Co Pyrrolidine gpr40 modulators.
MX2012004078A (en) 2009-10-09 2012-07-25 Irm Llc Compounds and compositions as modulators of gpr119 activity.
WO2011051966A2 (en) * 2009-10-12 2011-05-05 Ipca Laboratories Limited Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
WO2011050163A1 (en) 2009-10-21 2011-04-28 Wisconsin Alumni Research Foundation Method of preventing type 1 diabetes
AU2010313469A1 (en) 2009-10-29 2012-06-07 Merck Sharp & Dohme Corp. Bridged Bicyclic Piperidine Derivatives and methods of use thereof
JPWO2011052756A1 (en) 2009-10-30 2013-03-21 持田製薬株式会社 Novel 3-hydroxy-5-arylisoxazole derivatives
WO2011055770A1 (en) 2009-11-06 2011-05-12 武田薬品工業株式会社 Fused heterocyclic compound
WO2011057110A1 (en) 2009-11-06 2011-05-12 Ruprecht-Karls-Universitat-Heidelberg Gpr109a agonists for the treatment of cerebral ischemia
JP2013511571A (en) 2009-11-23 2013-04-04 ファイザー・インク Imidazo-pyrazoles as GPR119 inhibitors
US9301929B2 (en) 2009-11-24 2016-04-05 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
MY152710A (en) 2009-12-04 2014-11-28 Colgate Palmolive Co Oral compositions containing extracts of garcinia mangostana l. and related methods
EP2332427A1 (en) 2009-12-07 2011-06-15 Nestec S.A. low caloric fat replacers
WO2011072132A1 (en) 2009-12-09 2011-06-16 The Regents Of The University Of California Methods of treating inflammatory conditions
PL2513053T3 (en) 2009-12-18 2018-03-30 Ogeda Sa Pyrrolidine carboxylic acid derivatives as agonists of G-protein coupled receptor 43 (GPR43), pharmaceutical composition and methods for use in treating metabolic disorders
JP2013047188A (en) 2009-12-24 2013-03-07 Nippon Chemiphar Co Ltd Gpr119 agonist
US8476287B2 (en) 2009-12-25 2013-07-02 Mochida Pharmaceutical Co., Ltd. 3-hydroxy-5-arylisothiazole derivative
EP2345646A1 (en) 2010-01-14 2011-07-20 InterMed Discovery GmbH Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
WO2011092284A1 (en) 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
KR20120130104A (en) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Gpr119 agonist
CN101785763B (en) * 2010-02-04 2011-11-23 贵州天安药业股份有限公司 Metformin hydrochloride enteric-coated sustained release tablet and preparation method thereof
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
US20130023494A1 (en) 2010-04-06 2013-01-24 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP2013523822A (en) 2010-04-08 2013-06-17 ブリストル−マイヤーズ スクイブ カンパニー Pyrimidinyl piperidinyloxypyridino analogues as GPR119 modifiers
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
US8940716B2 (en) 2010-05-06 2015-01-27 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as GPR119 modulators
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
US8772323B2 (en) 2010-05-07 2014-07-08 Boehringer Ingelheim International Gmbh Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists
CA2799779A1 (en) 2010-05-17 2011-11-24 Thomas Daniel Aicher Piperidinyl-substituted lactams as gpr119 modulators
WO2011145718A1 (en) 2010-05-21 2011-11-24 田辺三菱製薬株式会社 Novel pyrrolo[2,3-d]pyrimidine compound
TW201202230A (en) 2010-05-24 2012-01-16 Mitsubishi Tanabe Pharma Corp Novel quinazoline compound
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
US20110293753A1 (en) 2010-05-28 2011-12-01 Louis Bellafiore Tocotrienol Compositions
WO2011151436A2 (en) 2010-06-04 2011-12-08 Euroscreen S.A. Novel compounds, method for use them and pharmaceutical composition containing them
GB201009873D0 (en) 2010-06-14 2010-07-21 Univ Leuven Kath Method for hydrogenation of isoalpha-acids (isohumulones) to hexahydro-iso-alpha-acids (hexahydro-isohumulones) by using heterogeneous ruthenium
JP5746334B2 (en) 2010-06-16 2015-07-08 シマベイ セラピューティクス， インコーポレーテッド GPR120 receptor agonist and use thereof
US20130096141A1 (en) 2010-06-18 2013-04-18 Bernard R. Neustadt Bicyclic heterocycle derivatives and methods of use thereof
EP2397039A1 (en) 2010-06-21 2011-12-21 Abbott Laboratories Compositions for delaying progression of diabetes using Salacia oblonga extract
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012006955A1 (en) 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. Compounds for treatment of metabolic disorders
SG187176A1 (en) 2010-07-23 2013-02-28 Connexios Life Sciences Pvt Ltd Agonists of gpr40
KR20120011357A (en) 2010-07-23 2012-02-08 현대약품 주식회사 Substituted pyridinone derivatives and methods for manufacturing the same
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
MX2013003034A (en) 2010-09-17 2013-08-15 Array Biopharma Inc Piperidinyl-substituted lactams as gpr119 modulators.
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN102432598A (en) 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 Tricyclic compound, preparation method thereof and pharmaceutical application thereof
EA022501B1 (en) 2010-10-08 2016-01-29 Кадила Хелзкэр Лимитед Gpr 119 agonists
JP2014001144A (en) 2010-10-08 2014-01-09 Nippon Chemiphar Co Ltd Gpr119 agonist
CA2813639A1 (en) 2010-10-08 2012-04-12 Mochida Pharmaceutical Co. Ltd. Cyclic amide derivative
CN101978956B (en) * 2010-10-13 2012-03-28 北京京丰制药有限公司 Metformin hydrochloride enteric-coated tablets and preparation method thereof
EP2632448B1 (en) 2010-10-30 2020-10-21 KinDex Pharmaceuticals, Inc. Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(-3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods
BR112013011865A2 (en) 2010-11-23 2016-08-23 Pfizer gpr119 modulators
CA2818050A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
AR084050A1 (en) 2010-12-01 2013-04-17 Boehringer Ingelheim Int INDANILOXIDIHIDROBENZOFURANILACETIC ACIDS
WO2012077655A1 (en) 2010-12-07 2012-06-14 塩野義製薬株式会社 Spiro derivative having gpr119 agonist activity
UY33805A (en) 2010-12-17 2012-07-31 Boehringer Ingelheim Int ? Dihydrobenzofuranyl-piperidinyl, aza-dihydrobenzofuranylpiperidinyl and diaza-dihydrobenzofuranyl-piperidinyl derivatives, pharmaceutical compositions containing them and uses thereof?
US8853213B2 (en) 2011-01-03 2014-10-07 Hanmi Pharm. Co., Ltd Bicyclic compound for modulating G protein-coupled receptors
US8778926B2 (en) 2011-01-21 2014-07-15 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
CN102617548A (en) 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 Bicycloheteroaryl compounds as GPR Receptor stimulant, compositions and application thereof
TW201309639A (en) 2011-02-17 2013-03-01 Lg Life Sciences Ltd Oxime derivatives as GPR119 agonists
US8822471B2 (en) 2011-03-14 2014-09-02 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9499467B2 (en) 2011-04-08 2016-11-22 Caldan Therapeutics Limited Ortho-fluoro substituted compounds for the treatment of metabolic diseases
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
BR112013027883A2 (en) 2011-04-27 2017-08-08 Mochida Pharm Co Ltd new 3-hydroxyisothiazole 1-oxide derivative
US9072758B2 (en) 2011-04-28 2015-07-07 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2012154009A2 (en) 2011-05-12 2012-11-15 한국화학연구원 Thienopyrimidine derivatives, pharmaceutically acceptable salts thereof, method for preparing thienopyrimidine derivatives, and pharmaceutical composition containing thienopyrimidine derivatives as active ingredients for preventing or treating diabetes-related diseases
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP6094578B2 (en) 2011-06-09 2017-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted piperidines as GPR119 modulators for the treatment of metabolic disorders
JP2014159376A (en) 2011-06-17 2014-09-04 Taisho Pharmaceutical Co Ltd Azaspiroalkane compound
CA2841757A1 (en) 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN102357088A (en) * 2011-10-26 2012-02-22 河北山姆士药业有限公司 Metformin hydrochloride enteric-coated tablet

Also Published As

Publication number Publication date
EP2872127A1 (en) 2015-05-20
CA2878625A1 (en) 2014-01-16
AU2013290100A1 (en) 2015-01-29
HK1210825A1 (en) 2016-05-06
IL236647A0 (en) 2015-02-26
WO2014011926A1 (en) 2014-01-16
JP2018087214A (en) 2018-06-07
CN104780915A (en) 2015-07-15
JP2015522080A (en) 2015-08-03

Similar Documents

Publication Publication Date Title
AR091739A1 (en) COMPOSITIONS AND METHODS TO REDUCE CARDIOMETABOLIC RISK
UY35040A (en) PIRROLOPIRIMIDINILAMINO-BENZOTIAZOLONAS REPLACED
GT201200276A (en) COMBINATIONS OF ACTIVE COMPOUNDS
CL2014000601A1 (en) Topical veterinary composition comprising at least one active agent derived from isoxazoline; and use of the composition for the treatment or prevention of an infestation or infection by parasites in an animal.
CL2014002087A1 (en) Chewable veterinary composition comprising as active agent an isoxazoline derivative compound; and its use for the treatment and / or prevention of an infestation and / or infection by parasites in an animal.
NI201500094A (en) SUBSTITUTE COMPOUNDS FOR PYRROLOPYRIMIDINE, COMPOSITIONS OF THE SAME, AND METHODS OF TREATMENT THEREOF.
CL2015001984A1 (en) (divisional sol. 1567-2013) combinations of active ingredients comprising pyridylethylbenzamides and other active ingredients.
BR112012023021A2 (en) indazole compounds and their uses
CU24336B1 (en) IMIDAZOPIRROLIDINONA COMPOUNDS
CL2015001389A1 (en) Compositions and anthelmintic compounds and methods for using them.
DOP2016000253A (en) NEW COMPOUNDS
UY33598A (en) IMIDAZOPIRIDAZINAS REPLACED
PE20142314A1 (en) INTRANASAL COMPOSITIONS OF DEXMEDETOMIDINE AND METHODS OF USE OF THEM
DOP2016000007A (en) SUBSTITUTED PIRAZOLPIRIDINS
NI201500118A (en) SUBSTITUTE IMIDAZOPYRIDAZINES
CU24349B1 (en) COMPOSITIONS INCLUDING 2,3-DIHYDROIMIDAZO [1,2-C] SUBSTITUTED KINAZOLINS USEFUL FOR TREATMENT OF CANCER
CO6741223A2 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
DOP2016000118A (en) TIENOPIRIMIDINS AS MKNK1 AND MKNK2 INHIBITORS
SV2017005466A (en) PIRAZOLPIRIDINAMINS AS INHIBITORS OF MKNK1 AND MKNK2
CL2017001239A1 (en) Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof. (divisional application 2831-2014)
CO6551731A2 (en) COMPOSITION OF COMBINATION UNDERSTANDING AS ACTIVE INGREDIENT L- CARNITINE OR PROPIONIL L-CARNITINE, FOR THE PREVENTION OR TREATMENT OF CRITICAL VENOUS INSUFFICIENCY
CL2016000300A1 (en) Therapeutic methods
DOP2016000251A (en) WNT SIGNALING ROAD INHIBITORS
MX359713B (en) Improved wound healing compositions comprising microspheres.
MX2017007856A (en) Oral care composition.

Legal Events

Date Code Title Description
FB Suspension of granting procedure